Suppr超能文献

糖尿病大鼠灌注心脏中脂蛋白脂肪酶的内皮结合位点并未减少。

Endothelial binding sites for lipoprotein lipase are not diminished in perfused hearts from diabetic rats.

作者信息

Liu L, Severson D L

机构信息

Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Canada.

出版信息

Can J Physiol Pharmacol. 1996 Nov;74(11):1204-9.

PMID:9028578
Abstract

The possibility that diabetes reduces functional, heparin-releasable lipoprotein lipase (HR-LPL) activity on the coronary vasculature of perfused hearts by altering endothelial binding sites for the enzyme was examined by measuring the binding and subsequent heparin-induced release of exogenous lipoprotein lipase purified from bovine milk (mLPL). Rat hearts were first perfused with heparin (5 U/mL) for 5 min to displace endogenous HR-LPL into the perfusate. The subsequent perfusion of control hearts with 0.05-2 micrograms/mL mLPL resulted in a progressive increase in bound exogenous enzyme that could be released by a second heparin perfusion. Induction of an acute, insulin-deficient model of diabetes (100 mg/kg streptozotocin 4-5 days prior to heart perfusions) reduced endogenous HR-LPL activity, but the binding and heparin-induced release of mLPL (0.5 microgram/mL) were the same as measured in control hearts. Therefore, diabetes does not alter low-affinity, high-capacity proteoglycan binding sites for mLPL on the endothelium of perfused hearts.

摘要

通过测量从牛乳中纯化的外源性脂蛋白脂肪酶(mLPL)的结合以及随后肝素诱导的释放,研究了糖尿病是否通过改变该酶在内皮细胞上的结合位点,从而降低灌注心脏冠状动脉血管上功能性、肝素可释放脂蛋白脂肪酶(HR-LPL)活性的可能性。首先用肝素(5 U/mL)灌注大鼠心脏5分钟,将内源性HR-LPL置换到灌注液中。随后用0.05 - 2微克/毫升mLPL灌注对照心脏,导致结合的外源性酶逐渐增加,且可通过第二次肝素灌注释放。诱导急性胰岛素缺乏型糖尿病模型(在心脏灌注前4 - 5天注射100毫克/千克链脲佐菌素)可降低内源性HR-LPL活性,但mLPL(0.5微克/毫升)的结合及肝素诱导的释放与对照心脏测量结果相同。因此,糖尿病不会改变灌注心脏内皮细胞上mLPL的低亲和力、高容量蛋白聚糖结合位点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验